208 related articles for article (PubMed ID: 16002078)
1. Effect of rosuvastatin on hepatic production of apolipoprotein B-containing lipoproteins in an animal model of insulin resistance and metabolic dyslipidemia.
Chong T; Naples M; Federico L; Taylor D; Smith GJ; Cheung RC; Adeli K
Atherosclerosis; 2006 Mar; 185(1):21-31. PubMed ID: 16002078
[TBL] [Abstract][Full Text] [Related]
2. Treatment with atorvastatin ameliorates hepatic very-low-density lipoprotein overproduction in an animal model of insulin resistance, the fructose-fed Syrian golden hamster: evidence that reduced hypertriglyceridemia is accompanied by improved hepatic insulin sensitivity.
Mangaloglu L; Cheung RC; Van Iderstine SC; Taghibiglou C; Pontrelli L; Adeli K
Metabolism; 2002 Apr; 51(4):409-18. PubMed ID: 11912545
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms of hepatic very low density lipoprotein overproduction in insulin resistance. Evidence for enhanced lipoprotein assembly, reduced intracellular ApoB degradation, and increased microsomal triglyceride transfer protein in a fructose-fed hamster model.
Taghibiglou C; Carpentier A; Van Iderstine SC; Chen B; Rudy D; Aiton A; Lewis GF; Adeli K
J Biol Chem; 2000 Mar; 275(12):8416-25. PubMed ID: 10722675
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of sphingolipid synthesis improves dyslipidemia in the diet-induced hamster model of insulin resistance: evidence for the role of sphingosine and sphinganine in hepatic VLDL-apoB100 overproduction.
Dekker MJ; Baker C; Naples M; Samsoondar J; Zhang R; Qiu W; Sacco J; Adeli K
Atherosclerosis; 2013 May; 228(1):98-109. PubMed ID: 23466071
[TBL] [Abstract][Full Text] [Related]
5. Effect of rosuvastatin on insulin sensitivity in an animal model of insulin resistance: evidence for statin-induced hepatic insulin sensitization.
Naples M; Federico LM; Xu E; Nelken J; Adeli K
Atherosclerosis; 2008 May; 198(1):94-103. PubMed ID: 18093597
[TBL] [Abstract][Full Text] [Related]
6. Dose-dependent effect of rosuvastatin on apolipoprotein B-100 kinetics in the metabolic syndrome.
Ooi EM; Barrett PH; Chan DC; Nestel PJ; Watts GF
Atherosclerosis; 2008 Mar; 197(1):139-46. PubMed ID: 17416370
[TBL] [Abstract][Full Text] [Related]
7. Tumor necrosis factor-alpha directly stimulates the overproduction of hepatic apolipoprotein B100-containing VLDL via impairment of hepatic insulin signaling.
Qin B; Anderson RA; Adeli K
Am J Physiol Gastrointest Liver Physiol; 2008 May; 294(5):G1120-9. PubMed ID: 18372392
[TBL] [Abstract][Full Text] [Related]
8. Inflammatory NF-kappaB activation promotes hepatic apolipoprotein B100 secretion: evidence for a link between hepatic inflammation and lipoprotein production.
Tsai J; Zhang R; Qiu W; Su Q; Naples M; Adeli K
Am J Physiol Gastrointest Liver Physiol; 2009 Jun; 296(6):G1287-98. PubMed ID: 19342510
[TBL] [Abstract][Full Text] [Related]
9. One-year efficacy and safety of rosuvastatin + fenofibric acid combination therapy in patients with mixed dyslipidemia: evaluation of dose response.
Ferdinand KC; Davidson MH; Kelly MT; Setze CM
Am J Cardiovasc Drugs; 2012 Apr; 12(2):117-25. PubMed ID: 22263674
[TBL] [Abstract][Full Text] [Related]
10. Rosuvastatin reduces plasma lipids by inhibiting VLDL production and enhancing hepatobiliary lipid excretion in ApoE*3-leiden mice.
Delsing DJ; Post SM; Groenendijk M; Solaas K; van der Boom H; van Duyvenvoorde W; de Wit EC; Bloks VW; Kuipers F; Havekes LM; Princen HM
J Cardiovasc Pharmacol; 2005 Jan; 45(1):53-60. PubMed ID: 15613980
[TBL] [Abstract][Full Text] [Related]
11. Attainment of goal/desirable lipid levels in patients with mixed dyslipidemia after 12 weeks of treatment with fenofibric acid and rosuvastatin combination therapy: a pooled analysis of controlled studies.
Roth EM; Rosenson RS; Jones PH; Davidson MH; Kelly MT; Setze CM; Lele A; Thakker K
J Clin Lipidol; 2012; 6(6):534-44. PubMed ID: 23312049
[TBL] [Abstract][Full Text] [Related]
12. Hepatic very low density lipoprotein-ApoB overproduction is associated with attenuated hepatic insulin signaling and overexpression of protein-tyrosine phosphatase 1B in a fructose-fed hamster model of insulin resistance.
Taghibiglou C; Rashid-Kolvear F; Van Iderstine SC; Le-Tien H; Fantus IG; Lewis GF; Adeli K
J Biol Chem; 2002 Jan; 277(1):793-803. PubMed ID: 11598116
[TBL] [Abstract][Full Text] [Related]
13. Alteration of relation of atherogenic lipoprotein cholesterol to apolipoprotein B by intensive statin therapy in patients with acute coronary syndrome (from the Limiting UNdertreatment of lipids in ACS With Rosuvastatin [LUNAR] Trial).
Ballantyne CM; Pitt B; Loscalzo J; Cain VA; Raichlen JS
Am J Cardiol; 2013 Feb; 111(4):506-9. PubMed ID: 23237107
[TBL] [Abstract][Full Text] [Related]
14. Comparative effects of rosuvastatin and gemfibrozil on glucose, insulin, and lipid metabolism in insulin-resistant, nondiabetic patients with combined dyslipidemia.
Lamendola C; Abbasi F; Chu JW; Hutchinson H; Cain V; Leary E; McLaughlin T; Stein E; Reaven G
Am J Cardiol; 2005 Jan; 95(2):189-93. PubMed ID: 15642550
[TBL] [Abstract][Full Text] [Related]
15. A 12-week, prospective, open-label analysis of the effect of rosuvastatin on triglyceride-rich lipoprotein metabolism in patients with primary dyslipidemia.
Kostapanos MS; Milionis HJ; Filippatos TD; Nakou ES; Bairaktari ET; Tselepis AD; Elisaf MS
Clin Ther; 2007 Jul; 29(7):1403-14. PubMed ID: 17825691
[TBL] [Abstract][Full Text] [Related]
16. Effects of 20 mg rosuvastatin on VLDL1-, VLDL2-, IDL- and LDL-ApoB kinetics in type 2 diabetes.
Vergès B; Florentin E; Baillot-Rudoni S; Monier S; Petit JM; Rageot D; Gambert P; Duvillard L
Diabetologia; 2008 Aug; 51(8):1382-90. PubMed ID: 18535816
[TBL] [Abstract][Full Text] [Related]
17. Effect of niacin on high-density lipoprotein apolipoprotein A-I kinetics in statin-treated patients with type 2 diabetes mellitus.
Pang J; Chan DC; Hamilton SJ; Tenneti VS; Watts GF; Barrett PH
Arterioscler Thromb Vasc Biol; 2014 Feb; 34(2):427-32. PubMed ID: 24285582
[TBL] [Abstract][Full Text] [Related]
18. Intestinal insulin resistance and aberrant production of apolipoprotein B48 lipoproteins in an animal model of insulin resistance and metabolic dyslipidemia: evidence for activation of protein tyrosine phosphatase-1B, extracellular signal-related kinase, and sterol regulatory element-binding protein-1c in the fructose-fed hamster intestine.
Federico LM; Naples M; Taylor D; Adeli K
Diabetes; 2006 May; 55(5):1316-26. PubMed ID: 16644688
[TBL] [Abstract][Full Text] [Related]
19. Rosuvastatin may modulate insulin signaling and inhibit atherogenesis beyond its plasma cholesterol-lowering effect in insulin-resistant mice.
Guo H; Lv H; Tang W; Chi J; Liu L; Xu F; Ji Z; Zhai X; Peng F
Cardiovasc Drugs Ther; 2012 Oct; 26(5):375-82. PubMed ID: 22918601
[TBL] [Abstract][Full Text] [Related]
20. New dimension of statin action on ApoB atherogenicity.
Chapman MJ; Caslake M; Packard C; McTaggart F
Clin Cardiol; 2003 Jan; 26(1 Suppl 1):I7-10. PubMed ID: 12539816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
